OBJECTIVE: This study examines the use of HLA typing for the diagnosis of celiac disease in a group of Australians with type 1 diabetes. RESEARCH DESIGN AND METHODS: Subjects included 131 sequential patients with type 1 diabetes (mean age 17 years [range 10-37]), 77 patients with biopsy-proven celiac disease (mean age 52 years [range 12-84]), and 162 healthy control subjects (mean age 17 years [range 2 months to 56 years]). Subjects were prospectively screened for celiac disease using endomysial antibodies (EMAs), tissue transglutaminase antibodies (TTGAs), and celiac disease-specific HLA typing. RESULTS: Celiac disease was diagnosed in 11 subjects after an intestinal biopsy (prevalence 8.4%). There was 95% agreement between TTGA and EMA for positive results and 100% for negative results. There was no significant difference for HLA DQ2 and DR4 among patients with type 1 diabetes with or without celiac disease. CONCLUSIONS: The prevalence of celiac disease among patients with type 1 diabetes is higher than previously estimated in Australia. TTGA is a valuable diagnostic tool that can be used for screening celiac disease in patients with type 1 diabetes. HLA typing should not be used in the diagnosis of celiac disease in patients with type 1 diabetes because of the similarities of HLA types between patients with type 1 diabetes and those with celiac disease.
OBJECTIVE: This study examines the use of HLA typing for the diagnosis of celiac disease in a group of Australians with type 1 diabetes. RESEARCH DESIGN AND METHODS: Subjects included 131 sequential patients with type 1 diabetes (mean age 17 years [range 10-37]), 77 patients with biopsy-proven celiac disease (mean age 52 years [range 12-84]), and 162 healthy control subjects (mean age 17 years [range 2 months to 56 years]). Subjects were prospectively screened for celiac disease using endomysial antibodies (EMAs), tissue transglutaminase antibodies (TTGAs), and celiac disease-specific HLA typing. RESULTS:Celiac disease was diagnosed in 11 subjects after an intestinal biopsy (prevalence 8.4%). There was 95% agreement between TTGA and EMA for positive results and 100% for negative results. There was no significant difference for HLA DQ2 and DR4 among patients with type 1 diabetes with or without celiac disease. CONCLUSIONS: The prevalence of celiac disease among patients with type 1 diabetes is higher than previously estimated in Australia. TTGA is a valuable diagnostic tool that can be used for screening celiac disease in patients with type 1 diabetes. HLA typing should not be used in the diagnosis of celiac disease in patients with type 1 diabetes because of the similarities of HLA types between patients with type 1 diabetes and those with celiac disease.
Authors: Heather J Galipeau; Nestor E Rulli; Jennifer Jury; Xianxi Huang; Romina Araya; Joseph A Murray; Chella S David; Fernando G Chirdo; Kathy D McCoy; Elena F Verdu Journal: J Immunol Date: 2011-09-12 Impact factor: 5.422
Authors: Alberto Rubio-Tapia; Ahmad S Abdulkarim; Russell H Wiesner; S Breanndan Moore; Patricia K Krause; Joseph A Murray Journal: Liver Int Date: 2008-04 Impact factor: 5.828
Authors: J A Tye-Din; D J S Cameron; A J Daveson; A S Day; P Dellsperger; C Hogan; E D Newnham; S J Shepherd; R H Steele; L Wienholt; M D Varney Journal: Intern Med J Date: 2015-04 Impact factor: 2.048
Authors: O A Makeeva; A A Sleptsov; E V Kulish; O L Barbarash; A M Mazur; E B Prokhorchuk; N N Chekanov; V A Stepanov; V P Puzyrev Journal: Acta Naturae Date: 2015 Jul-Sep Impact factor: 1.845
Authors: Robert P Anderson; Margaret J Henry; Roberta Taylor; Emma L Duncan; Patrick Danoy; Marylia J Costa; Kathryn Addison; Jason A Tye-Din; Mark A Kotowicz; Ross E Knight; Wendy Pollock; Geoffrey C Nicholson; Ban-Hock Toh; Matthew A Brown; Julie A Pasco Journal: BMC Med Date: 2013-08-28 Impact factor: 8.775
Authors: Gad Abraham; Jason A Tye-Din; Oneil G Bhalala; Adam Kowalczyk; Justin Zobel; Michael Inouye Journal: PLoS Genet Date: 2014-02-13 Impact factor: 5.917